Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestation

1 Jan 2000

Abstract excerpt

In a study of 2923 normal pregnancies and 203 pregnancies affected by trisomy 21 we have shown a significant difference in the median MoM of the markers: fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A in the presence of a female fetus compared with a male fetus. For maternal serum free beta-hCG levels are higher by 15% if the fetus is chromosomally normal and by 11% if the fetus has trisomy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Anomalies and Fetal Surgery
Share to Parvovirus B19 Infection Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10951481
DOI: 10.1002/1097-0223(200008)20:8<673::aid-pd880>3.0.co;2-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPMID 10951481Read ↗

The impact of fetal gender on first trimester nuchal translucency and maternal serum free β‐hCG and PAPP‐A MoM in normal and trisomy 21 pregnanciesSemantic proximity Read ↗

Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β -hCG and PAPP-A at 10-14 weeks of gestationSemantic proximity Read ↗

Maternal serum free ?-hCG and PAPP-A in fetal sex chromosome defects in the first trimesterSemantic proximity Read ↗

Screening for trisomy 13 by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationSemantic proximity Read ↗

Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancySemantic proximity Read ↗

First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristicsSemantic proximity Read ↗

Detection of sex chromosome abnormalities by nuchal translucency screening at 10–14 weeksSemantic proximity Read ↗

Screening for trisomy 21 in twin pregnancies in the first trimester using free ?-hCG and PAPP-A, combined with fetal nuchal translucency thicknessSemantic proximity Read ↗

A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester?Semantic proximity Read ↗

First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.